dc.contributor.author | Brock, CS | |
dc.contributor.author | Lee, SM | |
dc.date.accessioned | 2018-09-18T14:37:37Z | |
dc.date.issued | 2002-03 | |
dc.identifier | 3 | |
dc.identifier.citation | EUROPEAN RESPIRATORY JOURNAL, 2002, 19 pp. 557 - 570 | |
dc.identifier.issn | 0903-1936 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/2776 | |
dc.identifier.doi | 10.1183/09031936.02.00293002 | |
dc.description.abstract | The generation of new blood vessels, angiogenesis, is important for tumour proliferation and metastasis. This involves a number of interacting processes and factors, such as growth factors and the receptor tyrosine kinases, matrix metalloproteinases and integrins. Studies have shown that tumour vascularity and the overexpression of growth factors and their receptors are of independent prognostic importance in different cancers, including lung cancer. The present article provides a background to angiogenesis and describes the potential targets for anti-angiogenic and vascular targeting strategies in cancer, focusing specifically on carcinoma of the lung. It also describes the anti-angiogenic drugs presently under phase I, II and III investigation and highlights some of the problems associated with the standard methodologies for assessing tumour response and drug efficacy using these agents. | |
dc.format.extent | 557 - 570 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | EUROPEAN RESPIRATORY SOC JOURNALS LTD | |
dc.title | Anti-angiogenic strategies and vascular targeting in the treatment of lung cancer | |
dc.type | Journal Article | |
rioxxterms.versionofrecord | 10.1183/09031936.02.00293002 | |
rioxxterms.licenseref.startdate | 2002-03 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | EUROPEAN RESPIRATORY JOURNAL | |
pubs.notes | affiliation: Brock, CS (Reprint Author), Inst Canc Res, CRC, Ctr Canc Therapeut, Block E,Cotswold Rd, Sutton SM2 5NG, Surrey, England. UCL, Middlesex Hosp, Meyerstein Inst Oncol, London, England. keywords: anti-angiogenesis; lung cancer; vascular targeting keywords-plus: ENDOTHELIAL GROWTH-FACTOR; MATRIX-METALLOPROTEINASE INHIBITORS; HUMANIZED MONOCLONAL-ANTIBODY; SMALL-CELL; TUMOR ANGIOGENESIS; FACTOR EXPRESSION; BREAST-CANCER; THYMIDINE PHOSPHORYLASE; FACTOR RECEPTOR; PROGNOSTIC VALUE research-areas: Respiratory System web-of-science-categories: Respiratory System author-email: [email protected] researcherid-numbers: Lee, Siow Ming/C-1145-2013 orcid-numbers: Lee, Siow Ming/0000-0002-1741-6235 number-of-cited-references: 136 times-cited: 21 usage-count-last-180-days: 0 usage-count-since-2013: 0 journal-iso: Eur. Resp. J. doc-delivery-number: 533GT unique-id: ISI:000174521700028 oa: gold_or_bronze da: 2018-09-18 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR | |
pubs.volume | 19 | |
pubs.embargo.terms | Not known | |
dc.contributor.icrauthor | Brock, | en |